<DOC>
	<DOCNO>NCT01249456</DOCNO>
	<brief_summary>Title study : An observational , multicenter study safety efficacy Femara® ( Letrozole ) extend adjuvant treatment breast cancer patient complete adjuvant Tamoxifen Toremifen treatment Objectives : The major objective study assess safety efficacy Femara® woman undergone resection primary breast cancer subsequently receive prior adjuvant tamoxifen toremifen therapy 5 year real-life condition . The study aim follow objective : 1 . To identify unknown adverse reaction , especially serious adverse reaction 2 . To evaluate incidence description adverse reaction routine drug use 3 . To identify factor may affect safety Femara® 4 . To identify factor may affect efficacy Femara® Methodology : This open-label , multi-center , single-arm , observational phase IV study . Number center &amp; patient : Approximately 610 ( plan No . patient total study period ) patient 4 center enrol study . Population : Postmenopausal early breast cancer patient finish adjuvant treatment Tamoxifen Toremifen 5 year curative surgery `` indication '' describe local product labeling . Investigational drug : Femara® administer orally describe `` dose &amp; administration '' local product label 3 year . Study duration : FPFV May . 2006 , LPFV Dec. 2011 . Study drug administer 3 year renewal contract yearly basis .</brief_summary>
	<brief_title>Safety Efficacy Study Femara ( Letrozole ) Extended Adjuvant Treatment Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Written inform consent form Postmenopausal patient histologically cytologically confirm breast cancer remove time diagnosis evidence metastasis complete 5 year adjuvant therapy tamoxifen toremifen enter study Age ≥50 year cessation menses Age ＜50 year Postmenopausal status define one following : FSH level ＞ 3040 IU/L cessation menses past 1 year are/become amenorrheic due either chemotherapy LHRH , are/become amenorrheic due surgical ovarian ablation The tumor ER and/or PgRpositive receptor status could unknown No evidence recurrence disease entry Patient must accessible followup Those patient know receptornegative primary tumor Any concurrent malignancy Patients previously receive hormone replacement therapy ( HRT ) 5 year adjuvant therapy tamoxifen toremifen Patients currently receive aromatase inhibitor , chemotherapy Patients serious cardiovascular hepatic disease significantly abnormal daily function and/or laboratory result Life expectancy ＜ 12 month</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>